Skip to main content
. 2015 Oct 15;5(11):3350–3362.

Figure 7.

Figure 7

The anti-tumor efficacy of the combination of cisplatin and MLN4924 in a xenograft model of human cervical cancer. Nu/Nu nude mice bearing ME-180 or HeLa xenograft tumors were treated with DMSO (as non-treated control), cisplatin (1.2 mg/kg), MLN4924 (6 mg/kg) or the cisplatin/MLN4924 combination (1.2 mg/kg cisplatin plus 6 mg/kg MLN4924) by intraperitoneal injection once per day for 32 days. A. The tumor images represent excised tumors from each group. B. The tumor weights of each group (DMSO (as non-treated control), cisplatin, MLN4924 and combined treatment) measured on the last day of treatment were compared. C. The tumor volumes assessed during the different treatments are presented as the response. Quantitative analyses of tumor volumes are presented as the means ± SEM (n = 8 for each group of ME-180; n = 7 for each group of HeLa) and *P < 0.05 compared with cisplatin treatment alone or MLN4924 treatment alone.